Enterprise Value
453.4M
Cash
390.9M
Avg Qtr Burn
-30.2M
Short % of Float
29.21%
Insider Ownership
0.40%
Institutional Own.
-
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
JEMPERLI (Dostarlimb-gxly) Details Solid tumor/s, Cancer, Endometrial cancer | Approved Quarterly sales | |
Imsidolimab (ANB019) (anti-IL-36R) Details Ichthyosis, Palmoplantar pustulosis, Generalized pustular psoriasis, Hidradenitis suppurativa, EGFRi-mediated skin toxicity, Acne | Phase 3 Data readout | |
Dostarlimab Details Non-small cell lung carcinoma, Cancer | Phase 3 Data readout | |
Dostarlimab Details Ovarian cancer, Cancer | Phase 3 Data readout | |
Rosnilimab (ANB030) (anti-PD-1 agonist) Details Autoimmune disease, Rheumatoid arthritis | Phase 2b Data readout | |
Phase 2b Data readout | ||
Rosnilimab (ANB030) (anti-PD-1 agonist) Details Ulcerative colitis | Phase 2 Data readout | |
Etokimab (ANB020) Anti-IL-33 Details Chronic Rhinosinusitis with Nasal Polyps | Failed Discontinued | |
Rosnilimab (ANB030) (anti-PD-1 agonist) Details Alopecia areata, Vitiligo, Skin disease/disorder | Failed Discontinued |